Boston Biomedical, Inc.

1globe Health Institute LLC

Arqule, Inc.

1globe Biomedical Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Dana-farber-cancer Institute Inc.

International Institute of Cancer Immunology, Inc.

Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Oncology, Inc.

Beth Israel Deaconess Medical Center, Inc.

Sumitomo Pharma Oncology, Inc.

Globe Health Institute LLC

Globe Biomedical Co., Ltd.

Chiang Jia Li

Youzhi Li

Wei Li

David Leggett

Harry Rogoff

Mark Anthony Ashwell

Hitoshi Ban

Jifeng Liu

Shyam Unniraman

Xiangao Sun

Jason J Hill

Jean-Marc Lapierre

Manish Tandon

Seiji Kamioka

Arthur B Pardee

Zhiwei Jiang

Magdi Moussa

Neru Munshi

Masashi Goto

Syed M Ali

Toshio Nishihara

Yosuke Takanashi

Yukihiro Nishio

Yusuke Sawayama

Ji-Feng Liu

Naoaki Shimada

Yanbin Liu

David Vensel

Wataru Hirose

Toshihiko Sone

Suzhen Chen

Keith Mikule

Zoltan Derdak

Hannah Bader

Matthew Hitron

Kenneth Carl Anderson

Hiroki Yamaguchi

Hiroyuki Kitano

Shingo Tojo

Manabu Kusagi

Tomoyuki Furuta

Johannes Fruehauf

David Kerstein

Nobuyuki Sawada

Keyur Gada

Xiaoshu Dai

Shoukou Ri

Amanda Gibeau

Shuanglin Xiang

Tsuguteru Otsubo

Eiji Sugaru

Stephen A Hill

Deepak Gupta

Mark Antony Ashwell

Alan Lau

Mithilesh Jha

Darko Stevanovic

Yuan Gao

Vaibhav Saxena

Henry Rogoff

Magdi M Moussa

Jason Hill

Namita Dodwadkar

Joseph Prata

Provided are compositions and methods relating to or derived from anti-PD-L1 antibodies with ADCC and/or CDC activities. More specifically, provided are fully human antibodies that bind PD-L1, PD-L1-binding antibody fragments, derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments.

Anti-PD-L1 cancer immunotherapy antibodies

The invention provides novel methods of treating or preventing obesity or overweight and closely associated comorbidities therewith in a mammalian subject including human.

Treatment for obesity

Novel compositions and methods relating to or derived from a rationally designed fusion protein composition combines a therapeutic antibody with an IL2 mutant that can simultaneously enhance anti-tumor immunity or derepress tumor-associated immunosuppression along with direct activation of effector cells by IL2 without activating Tare provided. The fusion protein can be used to prevent or therapeutically treat cancer.

Rationally designed protein compositions

The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5'-overhang, 3′-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.

Compositions of asymmetric interfering RNA and uses thereof

The invention provides novel methods of treating or preventing nonalcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH) in a mammal including a human.

Treatment for non-alcoholic fatty liver disease

The use of a pharmaceutical composition in treating cancer in a subject comprising a therapeutically effective amount of a compound of formula (I), a therapeutically effective amount of paclitaxel and a low dose of gemcitabine, and a kit included above composition thereof.

Combination solution for treating chemotherapy refractory cancer

Novel synthetic biology-based ADCC technologies are provided that enhance or enable ADCC responses, for example, through a rationally-designed soluble universal ADCC enhancer protein (SUAEP) where a high-affinity CD3-binding domain is fused to a high-affinity Fc-binding domain. The SUAEP technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.

Soluble universal ADCC-enhancing synthetic fusion gene and peptide technology and its use thereof

The invention provides novel compounds, pharmaceutical compositions and methods of preparation and use thereof for treating disease affecting the central nervous system such as multiple sclerosis.

Therapeutics for central nervous system disorders

A compound represented by the formula (1): wherein Xand Yare each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, Ris a hydrogen atom, a group represented by the formula (2): wherein Xand Yare each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

WT1 antigen peptide conjugate vaccine

A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.

Synthetic biology-based ADCC technology

A process for producing a hydrate of a hydrochloride salt of 2,2'-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid of the formula: wherein the process comprises the following step:

Process for producing a hydrate of a hydrochloride salt of 2,2'-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid

The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5'-overhang, 3&#x2032;-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.

The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.

Biodegradable and clinically-compatible nanoparticles as drug delivery carriers

This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N&#x2014;R; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; Rand Rare each independently a hydrogen atom, a halogen atom, or an optionally-substituted Calkyl carbonyl group, etc.; R, Rand Rare each independently a hydrogen atom, a halogen atom, or an optionally-substituted Calkyl carbonyl group, etc.; and Ris a hydrogen atom or an optionally-substituted Calkyl group, etc.]. 

Tricyclic quinone derivative

Growing community of inventors

Cambridge, MA, United States of America

Chiang Jia Li